{"id":872619,"date":"2025-08-07T08:40:19","date_gmt":"2025-08-07T12:40:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/"},"modified":"2025-08-07T08:40:19","modified_gmt":"2025-08-07T12:40:19","slug":"soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/","title":{"rendered":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy"},"content":{"rendered":"
\n

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire<\/a> \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire<\/a> (“NNW”), one of 70+ brands within\u00a0the\u00a0Dynamic Brand Portfolio<\/a>@IBN<\/a>\u00a0(InvestorBrandNetwork<\/a>)<\/u>, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.<\/p>\n

To view the full publication, \u201cClinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,\u201d please visit: https:\/\/nnw.fm\/QCrhc<\/a>\u00a0.<\/p>\n

As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults.\u00a0The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose.\u00a0Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years.\u00a0There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and effective treatments. <\/p>\n

The Trump administration’s “Make America Healthy Again” initiatives have highlighted this problem and focused on improving access to treatments and speeding up medical innovation.\u00a0Soligenix Inc. (NASDAQ: SNGX) is working to advance this mission with its HyBryte(TM) platform, a new therapy for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer that largely impacts older adults.\u00a0The company has successfully established U.S.-based manufacturing for HyBryte’s active ingredient, demonstrating the kind of domestic innovation that can significantly help this underserved patient group.\u00a0<\/p>\n

\n About <\/b>
\n Soligenix Inc.<\/b>\n <\/p>\n

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (\u201cSGX301\u201d or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (\u201cCTCL\u201d). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (\u201cSGX302\u201d) into psoriasis, the company\u2019s first-in-class innate defense regulator (\u201cIDR\u201d) technology, dusquetide (\u201cSGX942\u201d) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (\u201cSGX945\u201d) in Beh\u00e7et\u2019s disease.<\/p>\n

The company\u2019s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company\u2019s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix\u2019s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (\u201cNIAID\u201d), the Defense Threat Reduction Agency (\u201cDTRA\u201d) and the Biomedical Advanced Research and Development Authority (\u201cBARDA\u201d).<\/p>\n

For further information, visit the company\u2019s website at\u00a0www.Soligenix.com\u00a0<\/a>.<\/p>\n

\n NOTE TO INVESTORS:\u00a0<\/b>The latest news and updates relating to SNGX are available in the company\u2019s newsroom at\u00a0https:\/\/ibn.fm\/SNGX<\/a><\/p>\n

\n About NetworkNewsWire<\/strong>\n <\/p>\n

\n NetworkNewsWire<\/a>\u00a0(\u201cNNW\u201d) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within\u00a0the\u00a0Dynamic Brand Portfolio<\/strong><\/a>\u00a0@\u00a0IBN<\/strong><\/a>\u00a0that delivers:<\/strong>\u00a0(1) access to a vast network of wire solutions via\u00a0InvestorWire\u00a0to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;<\/strong>\u00a0(2) article and\u00a0editorial syndication to 5,000+ outlets<\/a>;<\/strong>\u00a0(3) press release enhancement<\/a>\u00a0to ensure maximum impact;<\/strong>\u00a0(4)\u00a0social media distribution<\/a>\u00a0via IBN to millions of social media followers;<\/strong>\u00a0and (5) a full array of tailored\u00a0corporate communications solutions<\/a>. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today\u2019s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.<\/p>\n

For more information, please visit\u00a0https:\/\/www.NetworkNewsWire.com<\/a><\/p>\n

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https:\/\/www.NetworkNewsWire.com\/Disclaimer<\/a><\/p>\n

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com<\/a>
212.418.1217 Office
Editor@NetworkNewsWire.com<\/a><\/p>\n

NetworkNewsWire is powered by\u00a0IBN<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cClinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,\u201d please visit: https:\/\/nnw.fm\/QCrhc\u00a0. As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults.\u00a0The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose.\u00a0Many of these rare … <\/p>\n

Continue reading “Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSoligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cClinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,\u201d please visit: https:\/\/nnw.fm\/QCrhc\u00a0. As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults.\u00a0The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose.\u00a0Many of these rare … Continue reading "Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T12:40:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy\",\"datePublished\":\"2025-08-07T12:40:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/\"},\"wordCount\":762,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/\",\"name\":\"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==\",\"datePublished\":\"2025-08-07T12:40:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk","og_description":"NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — via InvestorWire \u2014 Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within\u00a0the\u00a0Dynamic Brand Portfolio@IBN\u00a0(InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, \u201cClinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,\u201d please visit: https:\/\/nnw.fm\/QCrhc\u00a0. As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults.\u00a0The aging population’s increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose.\u00a0Many of these rare … Continue reading \"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T12:40:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy","datePublished":"2025-08-07T12:40:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/"},"wordCount":762,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/","name":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==","datePublished":"2025-08-07T12:40:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzE4MSM3MDg0NzQ0IzUwMDE0NzgxMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soligenix-inc-nasdaq-sngx-proprietary-platform-aims-to-meet-growing-need-for-effective-ctcl-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}